I am sure that we all know that, to ensure the efficacy and safety of anticoagulant therapy, which is usually given orally as warfarin, regular monitoring is essential to ensure that its effect stays within the therapeutic range. The dosage is adjusted according to the time that it takes for a blood sample to clot. Because serious complications can occur if warfarin is poorly controlled, it is vital for patient welfare that the clotting time is checked frequently. Traditionally, of course, that has been done through hospital-based anticoagulant clinics.
I first brought the issue of self-monitoring and self-management of anticoagulation therapy to the Parliament in 2010, because it appeared to me to be a cost-effective and beneficial way of enabling appropriate patients to be partners in their care, in line with the Government policy of encouraging self-monitoring and self-management of long-term conditions, when that can be done appropriately and safely.
At that time, Scotland lagged behind England and the rest of Europe, and that remains the situation today. Only 1 per cent of patients on warfarin in Scotland self-manage their treatment, whereas across the UK as a whole the figure is 2 per cent. Approximately 740 people in Scotland self-monitor out of 25,000 in the UK, but 70,000 people in Germany do so.
NHS boards in Scotland generally do not provide support for self-monitoring or self-management of anticoagulation therapy; for example, in NHS Greater Glasgow and Clyde only 40 adults self-manage, which is a quarter of 1 per cent of the 16,000 patients on the treatment, whereas there is very good provision in Yorkhill hospital for paediatric patients to self-manage. Unfortunately, as children in that area who can self-manage reach the age of transition to adult services, they have to return their monitors and go back to attending clinics for treatment. In fact, only three health boards in Scotland have protocols for self-management of transitional patients.
In my own region, NHS Tayside actively discourages patient self-monitoring, or PSM, and I am told that it has even refused support when PSM was recommended to a patient by a consultant cardiologist. NHS Grampian as yet gives no formal support, with the development of a protocol for self-monitoring being delayed due to a lack of enthusiasm for it from the various parties that need to be involved.
However, there is growing support for change and there are pockets of best practice in Scotland. A good example is Largs medical group, which is actively supporting 13 people to self-test through its active self-management service. Increasingly, there are drivers for change. For example, Scottish intercollegiate guidelines network guideline 129, on antithrombotics, states:
“Self monitoring and self dosing is safe and effective and can be considered for some patients.”
The Royal College of Physicians of Edinburgh also encourages the use of self-management, stating:
“Anticoagulant control may be improved by near patient testing and engaging patients in their own care; patient education should be supported at every stage.”
NHS Scotland’s 2020 vision for the NHS emphasises a focus on prevention, anticipation and supporting self-management, with the person at the centre of all decisions. Finally, the National Institute for Health and Care Excellence’s draft guidance recommends self-monitoring for people on long-term anticoagulation therapy. The final report by NICE on self-testing systems is due to be published in July, with the expectation that self-testing will be increasingly supported in England and Wales, which could let Scotland slip even further behind.
Unfortunately, the greatest resistance to self-testing for those who wish it seems to come from general practitioners and clinicians, according to the Anticoagulation Self-Monitoring Alliance. That point was brought out in a round-table discussion last year on the potential for the self-monitoring of anticoagulation that was attended by senior clinicians and patient groups and which resulted in four recommendations: first, that SIGN guideline 129 should be supported; secondly, that a review of the uptake of appropriate technology in Scotland compared with that in England and the rest of Europe should be undertaken; thirdly, that a learning-needs assessment for clinicians, GPs and other healthcare professionals should be carried out; and, fourthly, that consideration should be given to setting up a national service delivery model for anticoagulation to encourage health boards to promote self-management to appropriate patients.
On cost-effectiveness, studies carried out by the NHS in mid-Yorkshire and by health economists in the University of York showed that the NHS in Scotland could be saved around £600,000 a year from the prevention of strokes through the improved control of anticoagulation achieved by self-monitoring patients. Furthermore, all the patients who took part in the mid-Yorkshire study agreed that self-testing had been beneficial and would recommend it to others.
In her response to my earlier members’ business debate on the issue, the then health secretary, Nicola Sturgeon, was somewhat lukewarm about the self-management of anticoagulation, given earlier clinical advice and the fact that newer anticoagulant agents might replace warfarin. However, warfarin is still the treatment of choice for many patients, and expert advice is changing. Indeed, replies from the current health secretary to some recent parliamentary questions from my colleague Richard Lyle show that the Scottish Government is now taking account of SIGN guideline 129. However, with a rate of self-monitoring in Scotland that is still less than 1 per cent, something does not add up.
The response from the Government to another question from Richard Lyle about what support is available to patients in transition from paediatric to adult services was that local protocols for the delivery of anticoagulation management vary across Scotland but are in line with SIGN guideline 129 and that, at the time of transition, on-going warfarin management, including self-testing, would be agreed as part of an overall plan of healthcare—clearly, that is not generally the case.
Understandably it has been put to me that there is a significant difference between the answers that were given to Richard Lyle and the reality on the ground, where little or nothing appears to be happening by way of implementation. I would welcome the minister’s comments on that when he sums up because the Government needs to do more to ensure that patients are given the option to self-manage than just saying that that is the case.
I will conclude my speech as I did my 2010 speech, because it is still relevant to do so, by urging the Government to look closely at how anticoagulant therapy is managed and to consider investigating the potential for increasing self-testing and self-management with a view to rolling it out across health boards to suitable patients, thus saving the NHS money and improving the quality of care for the large and increasing number of people in Scotland who need long-term anticoagulation therapy.
17:10